Related references
Note: Only part of the references are listed.Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication
Charupong Saengboonmee et al.
CANADIAN JOURNAL OF DIABETES (2021)
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Oliver Clements et al.
JOURNAL OF HEPATOLOGY (2020)
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Postoperative hyperglycemia affects survival after gastrectomy for cancer: A single-center analysis using propensity score matching
Claudio Fiorillo et al.
SURGERY (2020)
Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient
Banchob Sripa et al.
HUMAN CELL (2020)
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
Chi Luo et al.
CANCER RESEARCH (2020)
Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines
Unchalee Thonsri et al.
ANTICANCER RESEARCH (2020)
NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells
Charupong Saengboonmee et al.
LIFE SCIENCES (2020)
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Xinhua Song et al.
CLINICAL CANCER RESEARCH (2019)
The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis
Jichun Ma et al.
ACTA DIABETOLOGICA (2019)
Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity
Gunya Sittithumcharee et al.
HEPATOLOGY (2019)
Effects of hyperglycemia on the progression of tumor diseases
Wenjie Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
Saowaluk Saisomboon et al.
HELIYON (2019)
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Sunghwan Suh et al.
DIABETES & METABOLISM JOURNAL (2019)
High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
I-Ping Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis
Jessica L. Petrick et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response
Chao-Yuan Huang et al.
EUROPEAN JOURNAL OF CANCER (2018)
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
Devin Abrahami et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation
Chatchai Phoomak et al.
SCIENTIFIC REPORTS (2017)
Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-κB
Charupong Saengboonmee et al.
ANTICANCER RESEARCH (2017)
Targeting hexokinase II as a possible therapy for cholangiocarcinoma
Ubonrat Thamrongwaranggoon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
Hyperglycemia, tumorigenesis, and chronic inflammation
Shu-Chun Chang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Diabetes and Cancer: a Review of Current Knowledge
J. Wojciechowska et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2016)
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Per Hydbring et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation
Charupong Saengboonmee et al.
SCIENTIFIC REPORTS (2016)
Post universal health coverage trend and geographical inequalities of mortality in Thailand
Suchunya Aungkulanon et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2016)
Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma Association of diabetes mellitus and cholangiocarcinoma
Charupong Saengboonmee et al.
CANCER EPIDEMIOLOGY (2015)
Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol
Burak Cem Soner et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort
S. Schlesinger et al.
ANNALS OF ONCOLOGY (2013)
PP1 and PP2A phosphatases - cooperating partners in modulating retinoblastoma protein activation
Victoria Kolupaeva et al.
FEBS JOURNAL (2013)
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells
Takuro Hayashi et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Molecular mechanisms underlying RB protein function
Frederick A. Dick et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers
Hirokazu Ohashi et al.
CANCER SCIENCE (2012)
Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma
Jun-Xing Huang et al.
ONCOLOGY LETTERS (2012)
Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer
Cecilia Ahlin et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer
Wendy A. Cooper et al.
HISTOPATHOLOGY (2009)
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia
Kelly M. Jackman et al.
PEDIATRIC BLOOD & CANCER (2008)
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma
Domenico Alvaro et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
P Poikonen et al.
BRITISH JOURNAL OF CANCER (2005)
Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients
AA Bahnassy et al.
BMC GASTROENTEROLOGY (2004)
Cyclin a as a predictive factor for chemotherapy response in advanced head and neck cancer
M Rodriguez-Pinilla et al.
CLINICAL CANCER RESEARCH (2004)
Cyclin A and Ki-67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy
K Saarilahti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time
IR Bukholm et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
R Michalides et al.
BRITISH JOURNAL OF CANCER (2002)
Coexpression of cyclin A and β-catenin and survival in breast cancer patients
IRK Bukholm et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
